Dec 05, 2019 / 02:00PM GMT
Edward Andrew Tenthoff - Piper Jaffray Companies, Research Division - MD & Senior Research Analyst
I'm a senior biotech analyst at Piper Jaffray. And before I begin our discussion with John Maraganore, the CEO of Alnylam, I'm required to point out certain disclosures regarding the relationship between Piper and Alnylam, which are posted both at the back of the room and also at the registration desk.
So Alnylam is the undisputed leader, the undisputed heavyweight of RNAi therapeutics, now with 2 drugs approved and a rich pipeline of future RNAi therapies. Just 2 weeks ago, The Medicines Company was acquired by Novartis for almost $10 billion for Alnylam's discovered cholesterol-lowering drug, inclisiran.
Here today is a very good, very long-time friend, John Maraganore. John, thanks for being with us to discuss these exciting times for Alnylam.
John M. Maraganore - Alnylam Pharmaceuticals, Inc. - CEO & Executive Director
Thanks. Thank you, Ted, and it is exciting times for the company.
Edward Andrew Tenthoff -
Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference Transcript
Dec 05, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers